The debate continues, but this time with cystatin-C measurements. Read the #TenTweetNephJC summary here!
This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.
The debate continues, but this time with cystatin-C measurements. Read the #TenTweetNephJC summary here!
Welcome to #TenTweetNephJC tweetorial
— Nephrology Jrnl Club (@NephJC) September 13, 2022
✳️ 10 tweets to catch-up with #NephJC ✳️
Have you ever prescribed piperacillin-tazobactam? Or avoided it due to fear of causing AKI?
Read on to learn more about the ‘nephrotoxin’ versus ‘pseudonephrotoxin’ debate pic.twitter.com/ZKX1ElhZds